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Abstract
Helicobacter pylori (H. pylori) is a Gram-negative spiral bacterium commonly found 
in the stomach. Major part of the world’s population is infected with H. pylori and is at 
increased risk of severe gastritis, peptic ulcer disease, and gastric cancer. Most studied 
virulence factors of the bacterium are the cytotoxin-associated gene (CagA) and the vac-
uolating cytotoxin A (VacA). The H. pylori infection is diagnosed by invasive (histologi-
cal examination, culture, and rapid urease test, which require endoscopy and biopsy) 
and noninvasive methods (serology, urea breath test, and stool antigen test). H. pylori 
eradication is preferred for a long-term prevention of complications. Current treatments 
consist of antibiotics and adequate PPI dose and can be divided into two strands—with 
or without bismuth. Achieving an eradication rate of >90% is an indicator for effec-
tive treatment. Due to the increasing levels of antibiotic resistance, the standard triple 
therapy is largely replaced with a quadruple therapy, especially in countries with high 
resistance rates. Antimicrobial susceptibility testing should be performed after the 
second-line treatment failure, leading to an individualized patient treatment. Clear 
explanations and patients’ compliance are of great importance for a better outcome.
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1. Introduction
In the early 1980s, Helicobacter pylori (H. pylori) was discovered by Barry Marshall and 
Robin Warren. They reported its presence on mucosal tissue from the stomach of patients 
with gastritis and peptic ulcers [1]. Today, it is known that more than half of Earth’s 
population is infected with this Gram-negative spiral bacterium. In most cases, the infec-
tion is completely asymptomatic, but it is far from harmless as 10–15% of those infected 
will develop peptic ulcer disease or gastric cancer [2]. The type and severity of the disease 
depends on several factors, as characteristics of the colonizing strain, host immune 
response, smoking, high-salt diet, and presence of other concurrent infections [3].
H. pylori strains from different geographical areas show clear phylogeographic 
features. The bacterium follows the human migration and has co-evolved with humans 
for over at least 60,000 years [4]. The fecal-oral and oral-oral routes of transmission are 
most common, with close person-to-person contact required. Strains of H. pylori are 
usually isolated from gastric biopsy tissue specimens, but the bacterium can be recov-
ered also from saliva, gastric reflux fluid, diarrhea, and vomitus. Isolation and trans-
mission from contaminated water supplies and farm animals has also been reported [5].
H. pylori is “special” in many ways as it possesses several important enzymes that 
enable its survival in the hostile acidic environment. Such an enzyme is the urease, 
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which breaks down the urea to ammonia and carbon dioxide, hence neutralizing the 
hydrochloric acid. Moreover, H. pylori avoids clearance with the gastric emptying 
with a number of adhesion molecules and its 4–6 flagella. Important virulence factors 
are the cytotoxin-associated gene A (CagA) and the vacuolating cytotoxin A (VacA).
Even though H. pylori colonization is usually asymptomatic, it leads to chronic 
active gastritis in most patients and is associated with a number of other gastroduodenal 
diseases, including gastric and duodenal ulcer disease, distal gastric adenocarcinoma, 
primary gastric mucosal-associated lymphoid tissue (MALT) lymphoma, dyspepsia, 
atrophic gastritis, iron deficiency anemia, and idiopathic thrombocytopenic purpura.
This is why H. pylori eradication is preferred for a long-term prevention of the 
above-mentioned complications. Current H. pylori treatment consists of antibiotics 
and adequate PPI dose and can be divided into two strands—with or without bismuth. 
Achievement of an eradication rate >90% is an indicator for effective treatment [6].
2. H. pylori virulence factors
H. pylori strains are more virulent and are associated with more severe gastric 
mucosal damages when there is a cytotoxin-associated gene pathogenicity island 
(cag PAI) in their genome. The cag PAI region contains ~30 genes encoding a type IV 
secretion system (T4SS) as well as cytotoxin-associated gene A (CagA). The CagA is 
delivered into host gastric epithelial cells via T4SS. Inside the cells, CagA undergoes 
tyrosine phosphorylation at the Glu-Pro-Ile-Tyr-Al (EPIYA) motifs by Src kinases. 
There is a higher risk for gastric cancer development in chronic infection with H. 
pylori cagA-positive strains. Carcinogenesis requires two major events. One is inacti-
vation of tumor suppressor, and the other is the activation of oncoprotein. H. pylori 
CagA interacts with both of them and successfully disturbs their functions [7].
Vacuolating Cytotoxin (VacA) is also a major virulence factor present in almost 
all strains, and is highly polymorphic. VacA affects the cells with the induction of 
vacuole formation, mitochondrial dysfunction, modulation of signal transduction 
pathways, inhibition of T cell proliferation, and production of inflammatory cyto-
kines. To favor its action, VacA binds to receptors such as receptor protein tyrosine 
phosphatases (RPTPα and RPTPβ), low-density lipoprotein receptor-related 
protein-1 (LRP1), fibronectin, CD18, and sphingomyelin. RPTPβ promote to 
ulceration and LRP1 is involved in the induction of autophagy. There is an interac-
tion between cagA and VacA molecules, which is associated with the pathogenesis 
of gastric diseases. Therefore, further research on VacA may increase the knowledge 
of its role in the development of gastric disorders in H. pylori infection [7].
H. pylori expresses several major adhesins including BabA, SabA, LabA, OipA, 
and AlpAB. A closer association of the bacteria with the epithelium is thought to 
be mediated by them. They also increase the inflammation and damage of gastric 
mucosa by enhanced exposure to other virulence factors.
Duodenal ulcer-promoting gene A, dupA, is present in the tfs4 gene cluster and 
also the presence of the iceA1 allele of iceA is associated with increased risk for 
duodenal ulcer disease.
3. Helicobacter pylori-associated diseases
3.1 Dyspepsia
According to Rome III, functional dyspepsia (FD) is a symptomatic dyspep-
sia in the absence of structural or biochemical explanation after appropriate 
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investigation [8]. There are gastrointestinal symptoms that are associated with 
chronic dyspepsia as epigastric pain, epigastric burning, uncomfortable postpran-
dial fullness, and early satiation.
FD is one of the most common gastrointestinal diseases which affects the quality 
of life. Chronic dyspepsia symptoms, which are thought to be caused by H. pylori 
infection, are decided to be separated from FD and defined as H. pylori-associated 
dyspepsia (HpD) in the Kyoto Global Consensus Conference held on January 30–
February 1, 2014 [9]. In this meeting, patients who remain symptom free 12 months 
after eradication are considered to be cases of HpD, while patients who continue to 
experience dyspepsia even after H. pylori eradication will be considered as FD [10].
The evidence of the association between H. pylori infection and dyspepsia has 
been increasing. However, it is still unknown why most of individuals with H. pylori 
infection have no symptoms, while some of them have chronic dyspepsia symp-
toms. Recent meta-analysis of 103 reports containing 312,415 individuals showed 
that the prevalence of uninvestigated dyspepsia was higher in H. pylori-positive 
individuals (OR 1.18; 95% CI 1.04–1.33) [11]. There is evidence of a small but 
statistically significant benefit in eradicating H. pylori in H. pylori-positive dys-
pepsia. Therefore, the eradication therapy is recommended as first-line therapy for 
H. pylori-positive dyspepsia. Zhao et al. reviewed 14 randomized controlled trials 
which contained information on the long-term (12 months or more) effects of H. 
pylori eradication on dyspeptic symptoms, and a sub-group analysis on geographi-
cal regions was conducted [12].
3.2 Gastritis
H. pylori swims through the layers of protective mucus of the gastric mucosa 
to avoid damage from gastric acid and digestive enzymes. The bacterium is able 
to interact with the mucins via major adhesins the blood group antigen-binding 
adhesin (BabA), sialic acid-binding adhesin (SabA), and the lacdiNAc-specific 
adhesin, LabA [13–15].
H. pylori activates inflammatory gene when the bacterium reach to gastric epi-
thelial cells. This is possible due to interaction with Toll-like receptor 2 and NOD1 
[16], and inflammasomes [17, 18]. Inflammatory signaling in gastric epithelial cells 
is activated by a number of different mechanisms, resulting in the secretion of 
cytokines and chemokines, including interleukin-8 (IL-8), IL-1b, tumor necrosis 
factor alpha (TNFa), IL-6, IL-12, CCL2-5, CCL20, and CXCL1-3 [19]. The chemo-
kines leads to the accumulation of neutrophils, macrophages, mast cells, dendritic 
cells (DCs), innate lymphoid cells, and lymphocytes—gastritis [4].
Neutrophils, macrophages, and NK cells contribute to gastritis via the secre-
tion of inflammatory and tissue-damaging factors including reactive oxygen and 
nitrogen species (ROS and RNS) [20], perforin, and granzymes [21]. However, DCs 
are semi-mature and tolerogenic in H. pylori-infected gastric mucosa that stimulate 
the development of regulatory T cells (Tregs), which suppress inflammation [22].
It has recently been shown that retinoic acid (RA) is produced by human gastric 
epithelial cells and DCs regulates the level of inflammation. More intense inflamma-
tion and mucosal damage have been observed during H. pylori infection, because of 
reduction in RA [23]. Autoreactive antibodies against molecules, such as the parietal 
cell H+ and K+-ATPase, frequently induce the molecular mimicry of H. pylori. These 
antibodies may enhance inflammation and damage in the stomach [24]. In addition, 
the cytokines interferon-gamma (IFNc) and TNFa, secreted by Th1 cells, stimulate 
macrophages to secrete further pro-inflammatory factors. IL-17A, IL-17F, IL-21, 
and IL-22, secreted by Th17 cells, also stimulate the expression of ROS, RNS, and 
chemokines, leading to further inflammation and neutrophil recruitment [25].
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All of the above makes it clear that the hosts’ immune response is one of the 
major factors involved in the H. pylori infection pathogenesis. Thus, cytokines and 
other chemokines, prostaglandins, and their metabolites, as products of the innate 
response may be involved in the etiology of H. pylori-related diseases.
3.3 Peptic ulcer disease
Around 95% of duodenal ulcers and around 70% of gastric ulcers are H. pylori 
infection related [26, 27]. Hemorrhage or perforation are relatively common com-
plications and are associated with a significant mortality.
H. pylori infection leads to destruction of delta cells by chronic inflammation 
of the antrum. This leads to a reduction in the level of somatostatin secretion 
and therefore impaired inhibition of gastrin production by the G cells, causing 
hypergastrinemia. The elevated gastrin levels overstimulate the acid-producing 
parietal cells of the undamaged corpus (in the case of antral-predominant gastritis) 
resulting in hyperchlorhydria. The increased gastric acid output can result in gastric 
metaplasia of the duodenal epithelium. This allows H. pylori to colonize it and cause 
inflammation, possibly leading to duodenal ulceration.
On the other hand, in patients with corpus-predominant atrophy or pan-
gastritis, the acid output can be normal or reduced, explained by the loss of parietal 
cells. A state of hypochlorhydria is established, despite increased gastrin production 
from the H. pylori-infected antrum, preventing development of duodenal ulcers. 
Gastric ulcers develop due to inflammation and damage to the gastric mucosa. Pre-
malignant lesions and gastric adenocarcinoma may also develop [4, 28].
In those with reduced numbers of Tregs in their gastric mucosa, peptic ulceration 
is more frequently found thus impaired capacity to control the inflammation [19, 29]. 
The inflammation and damage are enhanced by gastric Th1 and Th17 cells inducing 
epithelial cells to express higher levels of MHC class II and activation of mitogen-
activated protein (MAP) kinases and transcription factors AP-1 and NF-jB [30].
3.4 Gastric adenocarcinoma
There are approximately 100,000 new cases of gastric cancer each year [31]. A 
majority of cases are registered in developing countries, half of them occurring in 
Eastern Asia. It is the fifth most common malignancy worldwide and the third most 
common cause of cancer-related death diagnosed usually at a late stage [32].
Depending on the location the gastric cancer can be divided into two subtypes:
• Cardia—arising from epithelial cells at the gastroesophageal junction.
• Non-cardia—arising from the distal stomach.
Cardia gastric cancers are thought to be mostly unrelated to H. pylori infection 
and have similar risk factors to those for esophageal adenocarcinoma and Barrett’s 
esophagus [30]. Up to 89% of cases of non-cardia gastric cancer is attributed to 
the infection with H. pylori. The risk of gastric cancer development for an infected 
individual is 1–2% [33].
The gastric cancer is classified histologically as two types [34]:
• intestinal—usually exophytic, often ulcerating, and are associated with intes-
tinal metaplasia of the stomach and are more common in proximal (fundus) 
location.
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• diffuse-type—poorly differentiated infiltrating lesions, which lead to the thick-
ening of the stomach (linitis plastica) and predominate in younger patients.
Patients with intestinal-type tumors appear to have a better prognosis than those 
with diffuse-type.
Chronic gastritis caused by H. pylori infection after several decades, leads to 
gastric gland atrophy, intestinal metaplasia, dysplasia, and finally adenocarcinoma. 
H. pylori eradication therapy reduces the incidence of atrophic gastritis, but the risk 
of gastric cancer development is reduced only if the eradication is administered prior 
to pre-malignant changes [35]. ROS/RNS-mediated DNA damage, the silencing of 
tumor suppressor genes via DNA methylation, histone epigenetic modifications, and 
epithelial-mesenchymal transition are associated with gastric carcinogenesis [36].
Genetically determined high expression of pro-inflammatory cytokines (IL-6, 
IL-8, TNFa, IL-1b), low expression of anti-inflammatory cytokines (IL-10, TGFb), or 
enhanced responsiveness to bacterial components (Toll-like receptors 1, 2, 4, 5, and 9) 
are associated with a higher risk of gastric adenocarcinoma [37, 38]. In the future, iden-
tification of molecular profiles for gastric cancer subtypes will lead to more personal-
ized clinical management, therapeutic targets and biomarkers for screening, prognosis, 
prediction of response to treatment, and monitoring of gastric cancer progression [39].
3.5 MALT lymphoma
Almost all patients with gastric MALT lymphoma have an active H. pylori infec-
tion with frequency of approximately 0.8 per 100,000 per year. Around 10% of 
cases are thought to be independent of H. pylori, but may be due to perhaps gastric 
non-pylori Helicobacters or undiagnosed H. pylori infection. Formation of lymphoid 
follicles in the gastric mucosa is induced by H. pylori-mediated inflammation, 
which is not present in the uninfected stomach [40]. Chronic inflammation and 
continuous antigenic stimulation lead to uncontrolled expansion of marginal zone 
B cells in these lymphoid follicles [41]. The tumor cells are commonly localized in 
the gastric mucosa and often remain to this site. However, in approximately 40% of 
cases, spreading to regional lymph nodes and more distant mucosal sites occurs. In 
around half of gastric lymphoma, low-grade MALT lymphomas may transform into 
more aggressive diffuse large B cell lymphomas (DLBCL), which have a considerably 
worse prognosis [41]. After H. pylori eradication treatment, there is a regression 
of the low-grade B cell MALT lymphomas. In one-quarter of cases a chromosomal 
translocation t(11; 18) is found. This is the most common genetic aberration in 
gastric MALT lymphoma. The non-responsiveness of gastric MALT lymphoma to H. 
pylori eradication therapy is also predicted by the presence of t(11; 18) [42]. Fusion 
between the activator protein-12 (AP-12) and MALT-1 genes lead to this chromo-
somal breakage and translocation. The product of this fusion stimulates activation 
of the transcription factor NF-jB, which regulates the expression of anti-apoptotic 
genes and cell survival [41]. Mutations in immunoglobulin heavy chain variable 
region (IGHV) genes are also frequently present [43]. There is growing evidence that 
host genetic factors play an important role in developing gastric MALT lymphoma.
4. Diagnosis
Diagnosis of H. pylori infection can be done with noninvasive methods— 
serology, urea breath test (UBT), stool antigen test (SAT)—and invasive  methods—
histology, culture, PCR, rapid urease test (RUT). Only locally validated tests should 
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be used. PPIs have an anti-H. pylori activity and decrease the load of H. pylori 
leading to false-negative results on urease test, UBT, and SAT [44]. H2 receptor 
antagonists have been shown to have minimal effect on the sensitivity of UBT, 
and antacids do not impair the sensitivity of UBT or SAT. H2-blockers do not have 
anti-H. pylori activity [45–47]. In contrast, the antibacterial activity of antibiotics 
and bismuth compounds necessitate their discontinuation for 4 weeks to allow an 
increase of a detectable bacterial load.
From the noninvasive methods, 13C-UBT is the best approach to the diagnosis of 
H. pylori infection, with high sensitivity and specificity [48–50]. It cannot be used 
in children and pregnant women, because it exposes the patients to radiation [51]. 
SAT may be less acceptable in some societies, but has a high sensitivity and specific-
ity [6]. Under certain clinical circumstances, it leads to a low bacterial load in the 
stomach and to a decreased sensitivity of all diagnostic methods except serology. 
These clinical situations include GI bleeding, atrophic gastritis, gastric MALT lym-
phoma, and gastric carcinoma. Because serology is able to detect past infection with 
H. pylori, it should not be used as a method to monitor effectiveness of eradication.
In clinical practice, when there is an indication for endoscopy, and there is 
no contraindication for biopsy, the rapid urease test (RUT) is recommended as a 
first-line diagnostic test [6]. The sensitivity of biopsy urease tests is approximately 
90%, and specificity is in the range of 95–100% [52]. It has been shown that the 
best biopsy sites for detection of H. pylori and assessment of atrophy are the lesser 
and greater curvature of the mid antrum, and the middle gastric body at the lesser 
and greater curvature [53]. This is supported by the updated Sydney System [54]. 
A maximum approach for gastric biopsies includes the incisura region at the lesser 
curvature. In the case of detection of gastric polyps, ulcerations, and suspicious 
focal lesions, further biopsies are necessary.
Most cases of H. pylori infection can be diagnosed from gastric biopsies using 
histochemical staining alone. In cases of chronic (active) gastritis in which H. pylori 
is not detected by histochemistry, immunohistochemical testing of H. pylori can be 
used as an accessory test. In the case of normal histology, no immunohistochemical 
staining should be performed [6].
The value of culture is primarily to perform AST for clarithromycin, levofloxa-
cin, metronidazole, rifamycin, and eventually, amoxicillin and tetracycline. Several 
studies, using tailored treatments based on H. pylori susceptibility to antibiotics in 
comparison with standard empirical triple therapy, have shown a better eradication 
rate and may be cost-effective [55, 56].
A panel of serological tests (GastroPanel), including serum Pg (PgI and PgII), 
gastrin 17 (G-17), and anti-H. pylori antibodies, has recently been proposed as 
“serological biopsy” in dyspeptic patients [57, 58]. In populations with a low 
prevalence of atrophic gastritis, the negative predictive value of the GastroPanel in 
identifying atrophic gastritis is as high as 97% (95% CI 95–99%) [59].
In the post-treatment evaluation, UBT is a valid and reliable test in the assess-
ment of H. pylori eradication [60]. SAT can be used as an alternative [61]. Testing 
to prove eradication should be performed at least 4–8 weeks after completion of H. 
pylori therapy. PPI should be discontinued for at least 2 weeks [48, 61–63].
5. Treatment
Recommended treatment regimens [64]:
Clarithromycin triple—PPI (standard or double dose twice daily) + clarithro-
mycin (500 mg twice daily) + amoxicillin (1 g twice daily) OR metronidazole 
(500 mg three times daily) for 14 days.
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Bismuth quadruple—PPI (standard dose twice daily) + bismuth subcitrate 
(120–300 mg 4 times daily) or subsalicylate (300 mg 4 times daily) + tetracycline 
(500 mg 4 times daily) + metronidazole (250 mg 4 times daily or 500 mg 3–4 times 
daily) for 10–14 days.
Concomitant—PPI (standard dose twice daily) + clarithromycin (500 mg twice 
daily) + amoxicillin (1 g twice daily) + nitroimidazole (500 mg twice daily).
Suggested [64]:
Sequential—PPI (standard dose twice daily) + amoxicillin (1 g twice daily) 
for 5–7 days then PPI + clarithromycin (500 mg twice daily) + nitroimidazole5 
(500 mg twice daily) for 5–7 days.
Hybrid—PPI (standard dose twice daily) + amoxicillin (1 g twice daily) for 
7 days then PPI + amoxicillin + clarithromycin (500 mg twice daily) + nitroimid-
azole (500 mg twice daily) 7 days.
Levofloxacin triple—PPI (standard dose twice daily) + levofloxacin (500 mg 
daily) + amoxicillin (1 g twice daily) for 14 days.
Levofloxacin sequential—PPI (standard or double dose twice daily) + amoxi-
cillin (1 g twice daily) for 5–7 days then PPI + levofloxacin (500 mg daily) + nitro-
imidazole5 (500 mg twice daily) for 5–7 days.
LOAD—Levofloxacin (250 mg daily) + omeprazole (double dose 
daily) + nitazoxanide (500 mg twice daily) + doxycycline (100 mg daily) for 
7–10 days.
Eradication rates of H. pylori have been declining, because of the increasing 
resistance rates to antibiotics worldwide [65]. Such evidence comes from stud-
ies in Europe, Japan, Korea, China, Iran, Greece, Bulgaria, and others [66–71]. 
Clarithromycin resistance rates have now reached ~30% in Italy and Japan, ~40% in 
Turkey, and ~50% in China, although rates in Sweden and Taiwan were ~15%. The 
standard triple therapy is less effective nowadays, because of a number of reasons 
such as lower compliance, high gastric acidity, high bacterial load, and bacterial 
strains, but mainly due to the increase in H. pylori resistance to clarithromycin. H. 
pylori is now an inconstantly susceptible bacterium (10–50% resistant) except in 
Northern Europe. The choice of therapy should be based on the frequency of met-
ronidazole and dual clarithromycin and metronidazole resistance. If metronidazole 
resistance is almost negligible (e.g., Japan), replacing clarithromycin for metroni-
dazole in triple therapy (i.e., PPI-metronidazole-amoxicillin) shows excellent cure 
rates [72]. However, metronidazole resistance can be partially overcome by increas-
ing the dose, frequency, and duration of the antibiotic.
All non-BQTs will be less effective in regions with dual resistance to clar-
ithromycin and metronidazole >15% [73]. Non-bismuth quadruple concomitant 
therapy, prescribed for 14 days, can be an effective alternative in regions with 
high clarithromycin resistance (15–40%) but low to intermediate metronidazole 
resistance (<40%) [74]. Bismuth-containing quadruple therapies are the treat-
ment of choice when we have high (>15%) dual clarithromycin and metronida-
zole resistance. Ideally, clarithromycin should be avoided and a combination of 
alternative antibiotics. If bismuth is not available in high dual clarithromycin and 
metronidazole resistance areas, levofloxacin [75], rifabutin [76], and high dose 
dual (PPI + amoxicillin) [77] treatments can be considered. Quadruple therapy 
with a PPI, bismuth, and a combination of two antibiotics, among furazolidone, 
tetracycline, metronidazole, and amoxicillin, has been successfully tested (>90% 
cure rates) against H. pylori strains resistant to metronidazole, fluoroquinolones, 
and clarithromycin [78] and now is the recommended first-line treatment [79]. 
BQT should be considered effective provided the doses are sufficient and the dura-
tion should be extended to 14 days, unless 10 day therapies are proven effective 
locally [80, 81]. The combination of PPI, bismuth, metronidazole, and tetracycline 
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lasting 10–14 days achieved ≥85% eradication rate, even in areas with a high 
prevalence of metronidazole resistance [82–84].
Sequential therapy is more complex and requires switching of antibiotic drugs 
during the treatment course, which can confuse the patients. Concomitant therapy 
(PPI, amoxicillin, clarithromycin, and a nitroimidazole administered concurrently) 
is easier and similar to standard triple therapy and should be the preferred non-bis-
muth quadruple therapy. Sequential therapy achieves lower cure rates compared to 
concomitant therapy against clarithromycin-resistant strains [85, 86]. All non-BQTs 
(concomitant, hybrid, triple, and sequential) lead to excellent cure rates against 
susceptible H. pylori strains, but the cure rate will always be <90% when the rate of 
dual resistant strains is >5, >9, or >15%, respectively [73].
Response to PPI is individual and determined by cytochrome 2C19 and MDR 
polymorphisms. Caucasian subjects show a higher prevalence of high metabolizers 
(56–81%) compared to Asian [74]. Esomeprazole and rabeprazole provide bet-
ter overall H. pylori eradication rates, especially esomeprazole 40 mg twice daily, 
whereas rabeprazole 10 and 20 mg twice daily [87–92]. By raising pH, H. pylori enters 
the replicative state and become susceptible to amoxicillin and clarithromycin [93].
For second-line treatment, after failure of PPI-clarithromycin-amoxicillin triple 
therapy, a bismuth-containing quadruple therapy or a fluoroquinolone-containing 
triple or quadruple therapy are recommended [94]. In theory, any treatment 
could be used after failure of BQT, including repeating the same BQT with longer 
duration and high metronidazole dosage. However, treatment that has already 
failed seems wiser never to be repeated. Bismuth therapies are usually proposed 
as first-line treatments for areas of high clarithromycin resistance and using a 
clarithromycin-containing treatment as second-line therapy after failure of a BQT 
does not seem to be practical. That is why Levofloxacin-based triple therapy, that 
is known to be effective as second-line therapy after clarithromycin-containing 
therapy, should also be recommended after failure of a bismuth-containing qua-
druple regimen [95, 96]. The incidence of side effects are lower with levofloxacin-
containing triple therapy than with bismuth-containing quadruple therapy [97]. 
A sub-group analysis showed similar eradication rates with 500 and 1000 mg) of 
levofloxacin [97]. However, the efficacy of levofloxacin-based regimens may be 
affected by an increased prevalence of levofloxacin resistance [98]. Therefore, 
14-day bismuth quadruple therapy is a valid second-line treatment for H. pylori 
eradication, especially in areas with high fluoroquinolones resistance. Combining 
bismuth and levofloxacin in a 14-day quadruple therapy is an effective (≥90% cure 
rate), simple, and safe second-line strategy in patients [99]. Bismuth overcomes 
clarithromycin and levofloxacin resistance, because of the synergistic effect with 
antibiotics [100, 101]. Therefore, the levofloxacin/bismuth-containing quadruple 
therapy constitutes an encouraging second-line strategy not only in patients failing 
previous standard triple therapy, but also in non-bismuth quadruple “sequential” or 
“concomitant” treatments.
After failure of the first-line treatment (clarithromycin based) and second-line 
treatment (with bismuth-containing quadruple regimen), it is recommended to 
use the fluoroquinolone-containing regimen as a rescue therapy. After failure of the 
first-line treatment (triple or non-bismuth quadruple) and second-line treatment 
(fluoroquinolone-containing therapy), it is recommended to use the bismuth-based 
quadruple therapy. Furthermore, BQT is not influenced by clarithromycin and 
fluoroquinolone resistance [102]. However, if a second-line treatment fails, culture 
with susceptibility testing (AST) or molecular determination of genotype resistance 
is recommended. Susceptibility-guided triple therapies proved more effective than 
empirical triple therapies in first-line treatment [55, 103].
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6. Helicobacter pylori and extragastric diseases
Chronic infection with H. pylori may be favorable for certain gastroesophageal 
diseases, asthma, and other allergic disease manifestations and inflammatory bowel 
diseases (IBD). The beneficial role of H. pylori in GERD, Barrett’s esophagus (BE), 
and esophageal adenocarcinoma (EA) requires further clinical and experimental 
confirmation.
The reflux of gastric contents and the failure of the esophagus to clear by peri-
staltic contractions lead to GERD. The severity of the disease depends strongly on 
the pH of the refluxed gastric juice [104, 105]. Chronic GERDs most likely to cause 
BE—replacement of the stratified squamous epithelium with a metaplastic columnar 
epithelium. The inflammation caused by chronic acid exposure appear to promote the 
development of EA from BE [106]. Patients subjected to endoscopy for any indica-
tions have the prevalence of BE, which is approximately 1–2% up to 5–15% in patients 
with GERD symptoms. Patients with BE have a 30- to 125-fold higher risk for devel-
oping EA, in comparison with the general population [107].
In 2013, Rubenstein et al. found an inverse correlation of H. pylori with erosive 
esophagitis, especially in patients harboring CagA-positive strains [108]. This 
evidence was further supported by Korean and Japanese studies, in which H. pylori 
could be negatively linked with the risk and severity of erosive esophagitis [109, 110].
In 2012, Fischbach et al. documented a decreased risk of EA predominantly in 
patients infected with CagA-positive H. pylori strains and recently confirmed a 
negative association of H. pylori with the risk of BE [41, 111]. Nie et al. also found 
that CagA-positive H. pylori strains were associated with a decreased risk of EA in 
all populations, irrespective of geographical location [112].
Numerous studies have addressed whether H. pylori eradication promotes the 
development of GERD or associated diseases. However, recent studies have failed to 
corroborate an important clinical impact on GERD of H. pylori eradication.
Inflammatory bowel diseases (IBDs) are chronic relapsing disorders of increas-
ing incidence and two main forms—Crohn’s disease and ulcerative colitis. Intestinal 
inflammation and epithelial injury are characterized for the diseases. In Crohn’s 
disease, inflammation is discontinuous and can affect any part of the gastrointes-
tinal tract and all layers of the bowel wall. In contrast, ulcerative colitis expands 
continuously from the rectum and affect the superficial layer of the mucosa. 
Modern hygienic practices and diet have been proposed to account for the increas-
ing incidence of IBD in Western societies associated with changes in the human 
microbiota composition [113]. A correlation between H. pylori infection and IBD 
has long been suspected by gastroenterologists. There is a lower prevalence of H. 
pylori in IBD patients confirmed by studies, in which active H. pylori infection 
was detected by urea breath test rather than serum IgG or IgA [114–116]. A strong 
negative association between H. pylori colonization and IBD is presented in all 
meta-analyses and almost all original articles covering the topic [117–119].
7. H. pylori and the human microbiota
H. pylori is its best-known component of the stomach microbiota. In healthy 
conditions the main representatives of gastric microbiota are Streptococcus, 
Proteobacteria, Firmicutes, Bacteroidetes, and Actinobacteria [120–124]. The exact 
composition of a healthy gastric microbiota remains uncharacterized. The interac-
tion between the normal microbiota and H. pylori has not yet been fully defined. 
There is some evidence suggesting a predominance of H. pylori over other microbes 
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[120]. Non-H. pylori Helicobacter species can cause gastritis, peptic ulcer disease, 
gastric cancer, and gastric mucosa-associated lymphoid tissue lymphoma [125–130].
H. pylori eradication therapy can impair the healthy gut microbiota. The most 
relevant shifts involved are, respectively, Bacteroides, Bifidobacterium, Clostridium, 
Enterobacteriaceae, and Lactobacillus [131]. The most common GI side effects cor-
related with antibiotic therapy include diarrhea, nausea, vomiting, bloating, and 
abdominal pain [132]. Antibiotic administration is the main risk factor for the devel-
opment of C. difficile infection [133]. There is insufficient evidence on the effect of 
different eradication regimens and long-lasting impact of H. pylori eradication on the 
composition of gut microbiota. There are encouraging results, that probiotic supple-
mentation reduce the side effects of eradication [134–144]. Certain probiotics stains 
may have a better beneficial effect. There are evidence that Saccharomyces boulardii 
decreases the risk and overall adverse effects (RR 0.44, 95% CI 0.31 to 0.64) [145]. A 
number of meta-analyses of RCTs show a positive result that probiotics has the capac-
ity to increase the efficacy of H. pylori eradication therapies [134–144]. Despite these 
encouraging data, probiotics appear to increase the H. pylori eradication rate not by 
direct effects on H. pylori, but with reducing the side effects related to the therapy.
8. Conclusion
Helicobacter pylori has been part of the human population and migration since 
ancient times. Infection with the bacterium is an extremely significant disease and 
can lead to severe consequences for infected individuals. Treatment and the rising 
bacterial resistance are challenges that we encounter in everyday practice, according 
to the latest guidelines recommendations. We hope that in the future our knowledge 
will expand and we will be ready to present new approaches for H. pylori manage-
ment, because the bacterium will undoubtedly continue to be part of our microbiome.
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